GleamWall
中文EN

PLUR Pluri Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1158780 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY10.0%
TTM net income YoY-25.8%
TTM EPS YoY15.7%
Revenue 3-yr CAGR79.1%
Net income 3-yr CAGR—

Margins

Gross margin52.0%
Operating margin-2,341.1%
Net margin-1,943.9%
FCF margin-1,317.8%
EBITDA margin-2,306.0%

Returns

ROE—
ROA-96.8%
ROIC (approx.)—
Asset turnover0.05x

Leverage & solvency

Liabilities / assets167.1%
Debt / equity—
Current ratio0.27x
Interest coverage-36.77x

Cash quality & payout

Operating cash flow / net income0.66x
Accruals ratio-33.0%
Payout ratio—
Capex / revenue35.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q12026-09-302026Q4*2026-06-302026Q32026-03-312026Q22025-12-312026Q12025-09-302025Q4*2025-06-302025Q32025-03-312025Q22024-12-31
Income statement
Revenue$759,000$335,000$167,000$198,000$316,000$398,000$427,000$185,000
Cost of revenue$339,000$139,000$111,000$112,000$201,000$191,000$291,000$74,000
Gross profit$420,000$196,000$56,000$86,000$115,000$207,000$136,000$111,000
R&D expense$13.67M$3.37M$3.96M$3.83M$3.93M$3.99M$3.04M$2.92M
SG&A expense$2.32M$2.37M$2.63M$2.77M$2.53M$2.83M$2.49M$2.14M
Operating income-$15.57M-$5.55M-$6.54M-$6.51M-$6.35M-$6.62M-$5.40M-$4.96M
Interest expense$226,000$235,000$237,000$231,000$229,000$233,000$212,000$211,000
Pretax income-$15.38M-$6.19M-$6.18M-$6.88M-$6.14M-$7.77M-$6.33M-$3.11M
Income tax$12,000-$1,000-$8,000-$8,000-$8,000———
Net income-$10.39M-$5.88M-$5.55M-$6.54M-$5.85M-$7.60M-$6.15M-$2.96M
EBITDA-$15.44M-$5.42M-$6.41M-$6.38M-$6.22M-$6.51M-$5.33M-$4.89M
EPS (basic)-0.85—-0.55-0.71-0.65—-0.94-0.53
EPS (diluted)-0.85—-0.55-0.71-0.65—-0.94-0.53
Weighted avg. shares (diluted)12.18M—10.05M9.26M9.00M—6.56M5.55M
Balance sheet
Cash & equivalents$3.46M$3.53M$3.42M$4.69M$5.60M$7.20M$9.69M$8.29M
Current assets$8.94M$8.73M$10.46M$13.80M$16.92M$22.09M$27.45M$22.37M
PP&E, net—$1.57M—$1.72M$1.76M$1.82M$1.59M$911,000
Goodwill$3.14M$3.14M$3.14M$3.14M$3.14M$3.14M——
Intangibles$2.57M$2.61M$2.66M$2.70M$2.75M$2.79M——
Total assets$24.93M$24.88M$26.06M$30.60M$33.67M$38.68M$37.41M$30.86M
Current liabilities$32.83M$32.72M$32.01M$32.35M$32.16M$32.33M$5.71M$4.44M
Total liabilities$41.66M$42.31M$39.06M$39.81M$39.32M$39.55M$36.92M$33.78M
Shareholders' equity-$22.40M-$23.04M-$18.60M-$14.61M-$11.36M-$6.84M-$4.47M-$8.03M
Shares outstanding12.61M10.82M10.43M9.98M8.16M7.89M7.78M5.57M
Cash flow statement
Operating cash flow-$4.55M-$4.44M-$4.51M-$5.21M-$5.43M-$5.22M-$4.30M-$4.63M
Capital expenditure$3,000$26,000$44,000$447,000$116,000$721,000$577,000$112,000
Free cash flow-$4.55M-$4.47M-$4.56M-$5.65M-$5.54M-$5.94M-$4.88M-$4.74M
Investing cash flow$89,000$1.61M$1.79M$2.66M$3.85M$3.03M-$4.23M$8.64M
Financing cash flow$4.43M$2.82M$1.38M——-$435,000——
Depreciation & amortization$131,000$124,000$128,000$129,000$130,000$111,000$72,000$68,000
Stock-based compensation$238,000$476,000$395,000$763,000$1.35M$838,000$463,000$256,000

Free plan shows the latest 8 periods; Pro shows all 67 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.